Fibrogenic polymorphisms (TGF-β, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment

Journal of Investigative Medicine

Volumn 56, Issue 7, 2008, Pages 944-953

  Armendáriz Borunda, Juan ^a,b   Rincón, Ana Rosa ^a   Muñoz Valle, José Francisco ^a   Bueno Topete, Miriam ^a   Oregón Romero, Edith ^a   Islas Carbajal, María Cristina ^a   Medina Preciado, David ^b   González Garćia, Ignacio ^b   Bautista, Alfredo ^b   Garćia Rocha, Sergio ^b   Godoy, Jesús ^b   Mercado, Mónica Vázquez Del ^a   Troyo SanRoman, Rogelio ^a   Arellano Olivera, Inmaculada ^a,c   Lucano, Silvia ^a   Álvarez Rodŕiguez, Adriana ^a   Salazar, Adriana ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b OPD Civil Hospital Juan I Menchaca   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

AT; Cirrhosis; PAI 1; Pirfenidone; Polymorphisms; TGF

Indexed keywords

ANGIOTENSIN; GENOMIC DNA; PIRFENIDONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA; ANGIOTENSINOGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PRIMER DNA; PYRIDONE DERIVATIVE; SERPINE1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HEPATITIS C; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION SITE; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ALCOHOL LIVER CIRRHOSIS; GENETIC POLYMORPHISM; GENETICS; LIVER CIRRHOSIS; MEXICO; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

HEPATITIS C VIRUS;

ADULT; AGED; ANGIOTENSINOGEN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BASE SEQUENCE; DNA PRIMERS; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MEXICO; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PYRIDONES; TRANSFORMING GROWTH FACTOR BETA;

EID: 58149171859     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181891512     Document Type: Article

References (34)

1. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology. 2003;37:493-503.
2. Richardson MM, Powell EE, Barrie HD, et al. A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. J Med Genet. 2005; 42:e45 (http://www.jmedgenet.com/cgi/content/full/ 42/7/e45).
3. Friedman SL, Bansal MB. Hepatology. 2006;43(Suppl 1): S82-S88.
4. Tag CG, Mengsteab S, Hellerbrand C, et al. Analysis of the transforming growth factor-beta1 (TGF-beta1) codon 25 gene polymorphism by light cycle analysis in patients with chronic hepatitis C infection. Cytokine. 2003;24:173-181.
5. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetics factors disease progression on chronic hepatitis C. Hepatology. 2000;31:828-833.
6. Chaves FJ, Giner V, Corella D, et al. Body weight changes and the A-6G polymorphism of the angiotensinogen gene. Int J Obes. 2002;26:1173-1178.
7. Chen CH, Eng HL, Chang CJ, et al. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J Lab Clin Med. 2003;142: 100-105.
8. Zhang G, Kim H, Cai X, et al. Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephro-pathy. J Am Soc Nephrol. 2003;14:1254-1271.
9. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69:381-387.
10. Pralong G, Calandra T, Glauser MP. Plasminogen activator inhibitor-1: a new prognostic marker in septic shock. Thromb Haemost. 1989;61:459-462.
11. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739-10745.
12. Panahloo A, Mohamed-Ali V, Lane A, et al. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 1995; 44:37-42.
13. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non insulin-dependent diabetes mellitus. Thromb Haemost. 1995;74:842-847.
14. Armendáriz-Borunda J, Islas-Carbajal MC, Meza E, et al. A pilot study of a novel anti-inflammatory and anti-fibrotic agent, pirfenidone, in patients with liver cirrhosis. Hepatology. 2003;38(Suppl 1):308A.
15. Armendáriz-Borunda J, Islas-Carbajal MC, Meza-Garćia E, et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut. 2006;55(11):1663-1665.
16. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-293.
18. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003; 38:1449-1457.
19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
20. Elston RC, Forthofer R. Testing for Hardy-Weinberg equilibrium in small samples. Biometrics. 1977;33: 536-542.
21. Oliver J, Agundez JA, Morales S, et al. Polymorphisms in the transforming growth factor-beta gene (TGF-beta) and the risk of advanced alcoholic liver disease. Liver Int. 2005;25(5):935-939.
22. Wang H, Mengsteab S, Tag CG, et al. Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol. 2005; 11(13):1929-1936.
23. Albuquerque Pereira F, Pinheiro da Silva NN, Ferreira Rodart I, et al. Association of TGF-β1 Codon 25 (G915C) Polymorphism with hepatitis C virus infection. J Med Virol. 2008;80:58-64.
24. Garcia L, Hernandez I, Sandoval A, et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol. 2002;37:797-805.
25. Hernández-Cañaveral I, González J, López-Casillas F, et al. Amplified expression of dominant-negative transforming growth factor-beta type II receptor inhibits collagen type I production via reduced Smad-3 activity. J Gastroenterol Hepatol. 2004;19:380-387.
26. Gewaltig J, Mangasser-Stephan K, Gartung C, et al. Association of polymorphisms of the transforming growth factor-β1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta. 2002;316:83-94.
27. Baogui L, Ashwani K, Vijay S, et al. TGF-b1 DNA polymorphisms, protein levels, and blood pressure. Hypertension. 1999;33:271-275.
28. Blobe G, Shiemman W, Lodish H. Role of transforming growth factor β in human diseases. N Engl J Med. 2000; 342:1350-1358.
29. Bataller R and Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209-218.
30. Reisin E, Abel R, Modan M, et al. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med. 1978; 298:1-6.
31. Eriksson P, Kallin B, van t'Hooft FM, et al. Allelic specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92:1851-1855.
32. Margaglione M, Cappucci G, d'Addedda M, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants arteriosclerosis. Thromb Vasc Biol. 1998;18:562-567.
33. Dixon JB, Bhathal PS, Jonsson JR, et al. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol. 2003;39:967-971.
34. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247-2250.